DEF: Sensei Biotherapeutics 2026 Proxy: Acquisition & Financing

Sensei Biotherapeutics seeks stockholder approval for post-acquisition governance, share authorization, and equity plans following its merger with Faeth Therapeutics.

Summary

• The company completed the acquisition of Faeth Therapeutics on February 17, 2026, in a stock-for-stock transaction.
• Concurrent with the acquisition, the company raised $200 million in a private placement (PIPE) of Series B Preferred Stock.
• The company is seeking approval to convert Series B Preferred Stock into common stock, which will result in a change of control under Nasdaq rules.
• Stockholders are asked to approve an increase in authorized common stock from 12.5 million to 300 million shares.
• The company proposes adopting a 2026 Equity Incentive Plan and a 2026 Employee Stock Purchase Plan (ESPP).
• Following the acquisition, the company expects to rebrand as Faeth Therapeutics, Inc. and trade under the ticker 'FTH'.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-cautious event; while the $200 million capital injection provides a runway for the new PIKTOR program, the extreme dilution of legacy shareholders and the necessity of a change-of-control vote highlight the company's previous financial distress.

Positives

• Successfully raised $200 million in gross proceeds to fund clinical development.
• Acquisition of Faeth Therapeutics provides a new lead program, PIKTOR, an all-oral inhibitor for endometrial and breast cancer.
• The transaction structure preserved cash by avoiding a lengthy closing process.
• The company has secured support agreements from certain officers and directors representing approximately 1.5% of outstanding shares.

Negatives

• Significant dilution to existing stockholders; legacy equityholders now own approximately 4.9% of the company.
• The company's cash balance was declining prior to the acquisition, necessitating the strategic combination.
• The company failed to secure adequate financing or partnership options for its previous lead candidate, solnerstotug, through a Phase 2 trial.

Risks

• Failure to obtain stockholder approval for the conversion of Series B Preferred Stock and the authorized share increase could lead to mandatory cash settlement obligations.
• Failure to obtain Nasdaq approval for the listing application could materially harm the company's financial condition.
• The unaudited pro forma financial statements may not accurately reflect the future financial condition or results of operations of the combined company.
• The company may be required to adjourn the annual meeting multiple times if quorum or required votes are not met, increasing costs and diverting management attention.

Future Outlook

The company intends to use the $200 million in PIPE proceeds to advance the PIKTOR program through key clinical milestones, including a Phase 2 trial in endometrial cancer and a Phase 1b trial in breast cancer, while completing the ongoing Phase 1/2 trial of solnerstotug.

Management Comments

• The Board believes that combining the roles of Chairman and CEO under Mr. Parikh will foster unified leadership and enable more effective decision-making.
• The Board determined that Faeth Therapeutics merited serious consideration due to the development status of the PIKTOR program and public financing momentum.

Industry Context

StockSavvy.ai notes that this transaction reflects a common trend in the biotechnology sector where cash-constrained companies with struggling lead assets pursue reverse mergers with private companies that have more promising clinical-stage programs and access to fresh capital.

Comparison to Industry Standards

• The company's shift to a new lead program (PIKTOR) following a failed financing environment for its previous lead candidate (solnerstotug) is a standard survival strategy for small-cap biotech firms.
• The use of Series B Non-Voting Convertible Preferred Stock to facilitate a change of control and subsequent conversion is a common mechanism in private-to-public reverse mergers.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• The company is party to an investors rights agreement with certain 5% stockholders.

Stakeholder Impact

• Existing shareholders face significant dilution of their economic and voting interests.
• Employees and consultants are eligible for new equity incentive plans.
• Investors in the PIPE financing now hold a majority (54.5%) of the company's equity.

Next Steps

• Hold Annual Meeting on June 10, 2026.
• Obtain stockholder approval for share conversion and authorized share increase.
• Obtain Nasdaq approval for the listing application.
• Reconstitute the Board of Directors.
• Rebrand the company to Faeth Therapeutics, Inc. and change ticker to FTH.

Key Dates

Recommendation

The company is in a state of transition following a major acquisition and capital raise. Investors should wait to see if the new management team successfully executes the clinical development of the PIKTOR program and if the company maintains its Nasdaq listing status.

Keywords

Sensei Biotherapeutics, Faeth Therapeutics, PIKTOR, Proxy Statement, Biotechnology, Merger, PIPE Financing, Capital Raise